2020 연구자 정보 (22 / 991)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Franovic, Aleksandra (Franovic, A) |
Guardant Hlth Inc, Redwood City, CA USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Gold, Philip J. (Gold, PJ) |
Swedish Canc Inst, Seattle, WA USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Hochster, Howard S. (Hochster, HS) |
Yale Sch Med, New Haven, CT USA Rutgers Canc Inst New Jersey, New Brunswick, NJ USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Jeon, Hui-Jeon (Jeon, HJ) |
Daegu Gyeongbuk Med Innovat Fdn, New Drug Dev Ctr, Daegu 41061, South Korea |
|
|
[JCR상위 1.9%] Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity | SCIE | 1.9 |
BIOCHEMISTRY & MOLECULAR BIOLOGY CELL BIOLOGY |
ykchoi@knu.ac.kr kpark@knu.ac.kr |
||
|
Juergens, Rosalyn A. (Juergens, RA) |
McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada |
|
0000-0001-8627-4704 Juergens, Rosalyn |
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Kelly, Ronan J. (Kelly, RJ) |
Baylor Univ, Med Ctr, Dallas, TX USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Kim, Jae Sun (Kim, JS) |
Sungkyunkwan Univ, Sch Med, Seoul 16419, South Korea |
|
|
[JCR상위 1.9%] Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity | SCIE | 1.9 |
BIOCHEMISTRY & MOLECULAR BIOLOGY CELL BIOLOGY |
ykchoi@knu.ac.kr kpark@knu.ac.kr |
||
|
Kim, Sunnie (Kim, S) |
Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA Univ Colorado, Ctr Canc, Aurora, CO USA |
J-2750-2012 Kim, Tae-You |
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Knutson, Keith L. (Knutson, KL) |
Mayo Clin, Jacksonville, FL 32224 USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Lacy, Jill (Lacy, J) |
Yale Sch Med, New Haven, CT USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Lee, Jaebon (Lee, J) |
Sungkyunkwan Univ, Sch Med, Seoul 16419, South Korea |
JNT-2600-2023 Lee, Jaebon |
|
[JCR상위 1.9%] Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity | SCIE | 1.9 |
BIOCHEMISTRY & MOLECULAR BIOLOGY CELL BIOLOGY |
ykchoi@knu.ac.kr kpark@knu.ac.kr |
||
|
Li, Daner (Li, D) |
MacroGenics, Rockville, MD USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Lockhart, A. Craig (Lockhart, AC) |
Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea Washington Univ, Sch Med, St Louis, MO USA Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Marrone, Kristen A. (Marrone, KA) |
Johns Hopkins Univ, Baltimore, MD USA |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu | ||
|
Ng, Matthew C. H. (Ng, MCH) |
Duke NUS Med Sch, Natl Canc Ctr, Singapore, Singapore |
|
|
[JCR상위 1.9%] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu |
페이지 이동: